Effect of anovulatory drugs on the human urinary tract and urinary tract infections.
D000463:Algestone Acetophenide / Q000009:adverse effects; D001437:Bacteriuria / Q000175:diagnosis; D003276:Contraceptives, Oral / Q000009:adverse effects*; D004106:Dilatation / Q000139:chemically induced; D004958:Estradiol / Q000009:adverse effects; D005040:Ethynodiol Diacetate; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007434:Intrauterine Devices; D007674:Kidney Diseases / Q000139:chemically induced; D008656:Mestranol / Q000009:adverse effects; D011278:Pregnanes / Q000009:adverse effects*; D011372:Progestins / Q000009:adverse effects*; D011446:Prospective Studies; D012189:Retrospective Studies; D014546:Urinary Catheterization; D014552:Urinary Tract Infections / Q000382:microbiology*; D014566:Urogenital System / Q000187:drug effects* / Q000382:microbiology
D003276:Contraceptives, Oral; D011278:Pregnanes; D011372:Progestins; D004958:Estradiol; D005040:Ethynodiol Diacetate; D008656:Mestranol; D000463:Algestone Acetophenide